Many previous studies have demonstrated that botulinum toxin A (BTX-A) injections satisfactorily reduce spasticity. Nevertheless, BTX-A, with or without an adjuvant therapy, effectively improves the direct functional movement in few patients with spastic upper extremity paralysis. Therefore the present study aimed to determine the effectiveness of task-orientated therapy on spasticity and functional movement by using electromyography-triggered functional electrical stimulation (EMG-FES) after BTX-A injections. 
Introduction
Spasticity is a common sequela associated with lesions of the central nervous system. Spasticity of the upper extremity can interfere with the activities of daily living.
Although patients receive many traditional antispasticity treatments, including conventional physical and occupational therapy, systemic medication, tendon surgery, and the use of orthosis and focal neurolysis such as phenol injections, determining which is optimal is difficult.
In the early 1990s, botulinum toxin A (BTX-A) emerged as a commonly used clinical drug. Its use for treating spasticity leads to significant improvement in many patients.
Many previous studies 1 8 have demonstrated that after patients with spastic paralysis receive a BTX-A injection, they have better scores of the modified Ashworth scale and better range of motion (ROM). Nevertheless, the direct effects on upper extremity motor function 5, 7, 9 and grip strength 6 after BTX-A injection have been observed in few studies. Although BTX-A can reduce spasticity, BTX-A alone does not lead to a complete recovery from paralysis. Therefore, to facilitate the function of paretic muscles after spasticity is reduced, determining if there are more efficient therapies or rehabilitation is important.
Spasticity also activates abnormal synergy patterns .) The efficient facilitation of the paralysis and muscle reeducation are critical for a patient's rehabilitation; otherwise the patient would not be able to effectively achieve these actions simply from a BTX-A injection alone.
Thus, to achieve neurorehabilitation, therapies such as electromyography (EMG)-triggered functional electrical stimulation (FES) should be applied after BTX-A is injected. Patients with chronic spasticity paralysis who undergo phenol motor point block and task-oriented therapy with EMG-FES are reportedly more likely to have reduced spasticity and enhanced upper extremity functional improvement 11 . These findings suggest that a more active movement therapy, such as task-orientated therapy with EMG-FES, might be an effective treatment for patients with spastic paralysis after BTX-A is injected. Thus, the aim of the present open-label, prospective study was to assess the effectiveness of task-orientated therapy with EMG-FES after a BTX-A injection to improve upper extremity function in patients with spastic paralysis.
Materials and Methods
Subjects were eligible for inclusion in the study if they had had a stroke or spinal cord injury at least 6 months earlier and had motor impairment of the upper extremity due to paresis and focal spasticity. Exclusion criteria in- OG Giken Co., Ltd, Okayama, Japan) used in this study was a novel EMG-controlled electrical stimulator device that is referred to as an integrated volitional control electrical stimulator 12 . This device is a portable, 2-channel neuromuscular stimulator that can be used to elicit wrist and finger extension or shoulder flexion during coordinated movements (Fig. 1) . The system uses a 3-electrode format to allow EMG-FES of the muscles. Two selfadhesive electrodes (3 cm in diameter and separated by 3 cm) were placed over the belly of the target muscles.
The stimulation promotes finger, wrist, and/or elbow extension or shoulder flexion during coordinated movement but will not work when the muscles are quiescent.
Therefore, all subjects in the study were asked to start a voluntary contraction of the finger extensors. Surface electrodes detected the EMG signal at the target muscle. 
Results
The subjects were 15 patients (12 male and 3 female) val since the stroke or spinal cord injury was 37.9 months (range, 7 61 months) ( Table 1 ). All 15 subjects completed the study, and none had adverse events.
The median scores for the modified Ashworth scale decreased from 2 at baseline to 1 at both 10 days and 4 months (Fig. 2) . The mean FIMT score improved slightly but not significantly from 5.1 at baseline to 5.5 at 10 days (p=0.29) (Fig. 3) (Fig. 4 and 5 ). All changes of the STEF and BBT were statistically significant.
A similar response pattern was noted between the grip and release test and the grip strength ( Fig. 6 and 7) . 
Discussion
Although many studies have examined the efficacy of BTX-A, only a few studies have reported any changes in the detailed dexterity. A study by Hurvitz et al. 6 observed the movement of 9 children who had spastic upper extremity during the 24 weeks after receiving a BTX-A injection; however, the Ashworth scale measurement The simple test for evaluating hand function (STEF) at baseline (before injection) and 10 days and 4 months after botulinum toxin injection The STEF score decreased significantly from baseline after 10 days (from 17.1 to 13.3 *p<0.05) and then improved significantly after 4 months (23.3, **p<0.01). Fig. 5 Box and block test (BBT) at baseline (before injection) and 10 days and 4 months after botulinum toxin injection Similar to the STEF, the BBT decreased significantly from baseline after 10 days (14.5 to 12.4, **p<0.01) and then significantly increased after 4 months (17.7, **p<0.01). Fig. 6 Grip and release test (G&R test) at baseline (before injection) and 10 days and 4 months after botulinum toxin injection The G&R test score decreased only slightly from baseline at 10 days (4.7 to 4.2, p=0.26) but then increase significantly at 4 months (5.9, **p<0.05). Fig. 7 Grip strength (GS) at baseline (before injection) and 10 days and 4 months after botulinum toxin injection The GS decreased significantly from baseline after 10 days (14.5 to 10.8, **p<0.01) and returned to near baseline after 4 months (15.1, p=0.18 ). The change from baseline to 4 months was not significant.
showed no obvious correlation with the ROM, site of injection, or pinch force. The improvement in the less complex tasks, such as hand tapping, generally occurred at an earlier time point, whereas the more complex movements, such as forward reaching tasks, improved either later or not at all. The authors of the study concluded that the improvement seen in the pinch force after BTX-A was injected was due to the presence of more active hand usage 6 . Our results also support the hypothesis that more active hand usage is an important factor in the rehabilitation of such patients. Moreover, the active hand usage in our present study resulted in effective facilitation of the paretic muscles when EMG-FES was used. In addition, some of the task-orientated training movements that patients could not perform without EMG-FES were volitionally enabled with EMG-FES.
Our EMG-FES differs from the other types of FES 7, 9 , especially with regard to volitional movements. While an injection of BTX-A usually directly improves the spasticity, it occasionally reduces muscle strength via the transsynaptic mechanism. In contrast, the addition of EMG-FES to treatment with BTX-A improves muscle weakness via the transsynaptic mechanism, thereby being of benefit by improving upper extremity motor function.
It should be noted, however, that BTX-A has been re- Further studies should involve a large population and establish the long-term effects of our program.
